During the last session, Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX)’s traded shares were 11.53 million, with the beta value of the company hitting 1.69. At the end of the trading day, the stock’s price was $14.06, reflecting an intraday loss of -28.99% or -$5.74. The 52-week high for the QNRX share is $444.00, that puts it down -3057.89 from that peak though still a striking 74.54% gain since the share price plummeted to a 52-week low of $3.58. The company’s market capitalization is $125.98M, and the average intraday trading volume over the past 10 days was 3.42 million shares, and the average trade volume was 739.53K shares over the past three months.
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) trade information
Quoin Pharmaceuticals Ltd. (QNRX) registered a -28.99% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -28.99% in intraday trading to $14.06 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 204.49%, and it has moved by 83.19% in 30 days. Based on these gigs, the overall price performance for the year is -93.07%. The short interest in Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) is 0.99 million shares and it means that shorts have 0.2 day(s) to cover.
The consensus price target of analysts on Wall Street is $50.00, which implies an increase of 71.88% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $25.00 and $100.00 respectively. As a result, QNRX is trading at a discount of -611.24% off the target high and -77.81% off the low.
Quoin Pharmaceuticals Ltd. (QNRX) estimates and forecasts
Statistics show that Quoin Pharmaceuticals Ltd. has outperformed its competitors in share price, compared to the industry in which it operates. Quoin Pharmaceuticals Ltd. (QNRX) shares have gone down -24.00% during the last six months, with a year-to-date growth rate more than the industry average at 90.41% against 11.20.
While earnings are projected to return 37.90% in 2022.
Quoin Pharmaceuticals Ltd. is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX)’s Major holders
Quoin Pharmaceuticals Ltd. insiders own 17.47% of total outstanding shares while institutional holders control 11.42%, with the float percentage being 13.84%. Renaissance Technologies, LLC is the largest shareholder of the company, while 7 institutions own stock in it. As of Mar 30, 2022, the company held over 50400.0 shares (or 0.50% of all shares), a total value of $0.84 million in shares.
The next largest institutional holding, with 42665.0 shares, is of Virtu Financial LLC’s that is approximately 0.43% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $0.71 million.
Also, the Mutual Funds coming in first place with the largest holdings of Quoin Pharmaceuticals Ltd. (QNRX) shares are Fidelity NASDAQ Composite Index Fund and Trust For Professional Managers-PMC Diversified Equity Fund. Data provided on May 30, 2022 indicates that Fidelity NASDAQ Composite Index Fund owns about 14392.0 shares. This amounts to just over 0.14 percent of the company’s overall shares, with a $0.11 million market value. The same data shows that the other fund manager holds slightly less at 1550.0, or about 0.02% of the stock, which is worth about $8724.0.